HomeCompareISHI vs EQR

ISHI vs EQR: Dividend Comparison 2026

ISHI yields 2000000.00% · EQR yields 5.87%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ISHI wins by $4.879226400974806e+39M in total portfolio value
10 years
ISHI
ISHI
● Live price
2000000.00%
Share price
$0.00
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$4.879226400974806e+39M
Annual income
$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00
Full ISHI calculator →
EQR
EQR
● Live price
5.87%
Share price
$59.15
Annual div
$3.47
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$47.8K
Annual income
$5,475.61
Full EQR calculator →

Portfolio growth — ISHI vs EQR

📍 ISHI pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodISHIEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ISHI + EQR cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ISHI pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ISHI
Annual income on $10K today (after 15% tax)
$170,000,000.00/yr
After 10yr DRIP, annual income (after tax)
$4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/yr
EQR
Annual income on $10K today (after 15% tax)
$499.01/yr
After 10yr DRIP, annual income (after tax)
$4,654.27/yr
At 15% tax rate, ISHI beats the other by $4,146,934,558,431,324,500,000,000,000,000,000,000,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ISHI + EQR for your $10,000?

ISHI: 50%EQR: 50%
100% EQR50/50100% ISHI
Portfolio after 10yr
$2.439613200487403e+39M
Annual income
$2,439,373,269,665,485,000,000,000,000,000,000,000,000,000,000.00/yr
Blended yield
99.99%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

ISHI
No analyst data
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+18.9% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ISHI buys
0
EQR buys
0
No recent congressional trades found for ISHI or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricISHIEQR
Forward yield2000000.00%5.87%
Annual dividend / share$2.00$3.47
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8%
Portfolio after 10y$4.879226400974806e+39M$47.8K
Annual income after 10y$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$5,475.61
Total dividends collected$4.879195005460081e+39M$23.0K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: ISHI vs EQR ($10,000, DRIP)

YearISHI PortfolioISHI Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$200,010,700$200,000,000.00$11,380$679.82+$200.00MISHI
2$3,738,731,768,458$3,738,517,757,009.35$13,014$837.25+$3738731.76MISHI
3$65,315,062,866,930,490$65,311,062,423,938,240.00$14,961$1,036.20+$65315062866.92MISHI
4$1,066,400,830,062,625,000,000$1,066,330,942,945,357,500,000.00$17,297$1,289.22+$1066400830062625.00MISHI
5$16,272,182,796,453,826,000,000,000$16,271,041,747,565,660,000,000,000.00$20,121$1,613.15+$16272182796453826560.00MISHI
6$232,054,240,113,661,900,000,000,000,000$232,036,828,878,069,680,000,000,000,000.00$23,561$2,030.84+$2.3205424011366188e+23MISHI
7$3,092,799,066,104,688,500,000,000,000,000,000$3,092,550,768,067,767,400,000,000,000,000,000.00$27,783$2,573.54+$3.0927990661046884e+27MISHI
8$38,524,105,697,352,694,000,000,000,000,000,000,000$38,520,796,402,351,967,000,000,000,000,000,000,000.00$33,013$3,284.39+$3.8524105697352695e+31MISHI
9$448,468,826,014,798,700,000,000,000,000,000,000,000,000$448,427,605,221,702,600,000,000,000,000,000,000,000,000.00$39,547$4,223.51+$4.484688260147987e+35MISHI
10$4,879,226,400,974,806,000,000,000,000,000,000,000,000,000,000$4,878,746,539,330,970,000,000,000,000,000,000,000,000,000,000.00$47,791$5,475.61+$4.879226400974806e+39MISHI

ISHI vs EQR: Complete Analysis 2026

ISHIStock

Islet Holdings, Inc. offers skincare products in the United States. It provides acne-prone skin products, anti-aging products, berridroxies, botanical products, eye treatments, moisturizers and creams, sensitive skin products, toners and cleansers, and specialized products. The company also distributes skincare products of various other brands. It offers products online. Islet Holdings, Inc. was formerly known as Biozhem Cosmeceuticals, Inc. and changed its name to Islet Holdings, Inc. in May 2009. The company was incorporated in 1984 and is based in Grass Valley, California. It has a customer service center in Arizona.

Full ISHI Calculator →

EQRREIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this ISHI vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ISHI vs SCHDISHI vs JEPIISHI vs OISHI vs KOISHI vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.